170 related articles for article (PubMed ID: 28763226)
1. Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.
Nedelcovych M; Dash RP; Tenora L; Zimmermann SC; Gadiano AJ; Garrett C; Alt J; Hollinger KR; Pommier E; Jančařík A; Rojas C; Thomas AG; Wu Y; Wozniak K; Majer P; Slusher BS; Rais R
Mol Pharm; 2017 Oct; 14(10):3248-3257. PubMed ID: 28763226
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
Dash RP; Tichý T; Veeravalli V; Lam J; Alt J; Wu Y; Tenora L; Majer P; Slusher BS; Rais R
Mol Pharm; 2019 Oct; 16(10):4292-4301. PubMed ID: 31503493
[TBL] [Abstract][Full Text] [Related]
3. Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.
Rais R; Wozniak K; Wu Y; Niwa M; Stathis M; Alt J; Giroux M; Sawa A; Rojas C; Slusher BS
PLoS One; 2015; 10(7):e0131861. PubMed ID: 26151906
[TBL] [Abstract][Full Text] [Related]
4. Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA).
Rais R; Rojas C; Wozniak K; Wu Y; Zhao M; Tsukamoto T; Rudek MA; Slusher BS
J Pharm Biomed Anal; 2014 Jan; 88():162-9. PubMed ID: 24055700
[TBL] [Abstract][Full Text] [Related]
5. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
Nagel J; Belozertseva I; Greco S; Kashkin V; Malyshkin A; Jirgensons A; Shekunova E; Eilbacher B; Bespalov A; Danysz W
Neuropharmacology; 2006 Dec; 51(7-8):1163-71. PubMed ID: 16926034
[TBL] [Abstract][Full Text] [Related]
6. Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).
Hicks C; Gregg RA; Nayak SU; Cannella LA; Schena GJ; Tallarida CS; Reitz AB; Smith GR; Rawls SM
Psychopharmacology (Berl); 2017 Jun; 234(11):1671-1681. PubMed ID: 28251297
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism.
Xi ZX; Li X; Peng XQ; Li J; Chun L; Gardner EL; Thomas AG; Slusher BS; Ashby CR
J Neurochem; 2010 Jan; 112(2):564-76. PubMed ID: 19895667
[TBL] [Abstract][Full Text] [Related]
8. 2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice.
Luszczki JJ; Mohamed M; Czuczwar SJ
Eur J Pharmacol; 2006 Feb; 531(1-3):66-73. PubMed ID: 16403497
[TBL] [Abstract][Full Text] [Related]
9. Binding of the glutamate carboxypeptidase II (NAALADase) inhibitor 2-PMPA to rat brain membranes.
Tiffany CW; Cai NS; Rojas C; Slusher BS
Eur J Pharmacol; 2001 Sep; 427(2):91-6. PubMed ID: 11557259
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA).
Majer P; Jančařík A; Krečmerová M; Tichý T; Tenora L; Wozniak K; Wu Y; Pommier E; Ferraris D; Rais R; Slusher BS
J Med Chem; 2016 Mar; 59(6):2810-9. PubMed ID: 26930119
[TBL] [Abstract][Full Text] [Related]
11. GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity.
Thomas AG; Bodner A; Ghadge G; Roos RP; Slusher BS
J Neurovirol; 2009 Sep; 15(5-6):449-57. PubMed ID: 19995130
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons.
Tortella FC; Lin Y; Ved H; Slusher BS; Dave JR
Eur J Pharmacol; 2000 Aug; 402(1-2):31-7. PubMed ID: 10940354
[TBL] [Abstract][Full Text] [Related]
13. Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay.
Tallarida C; Song K; Raffa RB; Rawls SM
Amino Acids; 2012 Jun; 42(6):2521-4. PubMed ID: 21850438
[TBL] [Abstract][Full Text] [Related]
14. Existence of glia mitigated ketamine-induced neurotoxicity in neuron-glia mixed cultures of neonatal rat cortex and the glia-mediated protective effect of 2-PMPA.
Zuo D; Wang C; Li Z; Lin L; Duan Z; Qi H; Li L; Sun F; Wu Y
Neurotoxicology; 2014 Sep; 44():218-30. PubMed ID: 24931484
[TBL] [Abstract][Full Text] [Related]
15. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.
Date AA; Rais R; Babu T; Ortiz J; Kanvinde P; Thomas AG; Zimmermann SC; Gadiano AJ; Halpert G; Slusher BS; Ensign LM
J Control Release; 2017 Oct; 263():132-138. PubMed ID: 28159515
[TBL] [Abstract][Full Text] [Related]
16. NAALADase inhibition protects motor neurons against chronic glutamate toxicity.
Thomas AG; Corse AM; Coccia CF; Bilak MM; Rothstein JD; Slusher BS
Eur J Pharmacol; 2003 Jun; 471(3):177-84. PubMed ID: 12826236
[TBL] [Abstract][Full Text] [Related]
17. Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects.
Krečmerová M; Majer P; Rais R; Slusher BS
Front Chem; 2022; 10():889737. PubMed ID: 35668826
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation.
Thomas AG; Olkowski JL; Slusher BS
Eur J Pharmacol; 2001 Aug; 426(1-2):35-8. PubMed ID: 11525768
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats.
Long JB; Yourick DL; Slusher BS; Robinson MB; Meyerhoff JL
Eur J Pharmacol; 2005 Jan; 508(1-3):115-22. PubMed ID: 15680261
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis.
Hollinger KR; Alt J; Riehm AM; Slusher BS; Kaplin AI
Brain Res; 2016 Mar; 1635():105-12. PubMed ID: 26826008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
